Ancheng Biotech AC-1101 approved by Health Canada for first human clinical trial
-
Last Update: 2020-06-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The aphase of AC-1101 clinical trials is an open label, fixed sequence, and two periods of comparative bioavailability studiesThis trial compared the bioavailability and safety of the two products by using AC-1101 gel in local multi-dose localuse of healthy adult volunteers to correspond to a single oral dose control productThe trial is expected to be completed by the end of 2020AC-1101 is used to treat inflammatory skin diseases, and this clinical trial is intended to assess the pharmacokinetics and safety of the human body in addition to the use of gels, and to observe the correlation with other market-based oral productsThe results of phase I clinical studies will help plan the dose range and the propulsion milestone for the next clinical trial(Cuts in the original text)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
